NCT02135159View on ClinicalTrials.gov

Patients With Brain Metastases From HER2-positive Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

February 28, 2017

Study Completion Date

March 31, 2017

Conditions
HER2-positive Breast Cancer
Interventions
DRUG

TDM1

administration of the TDM1 by IV perfusion

RADIATION

Brain Sequential RT

local RT

Trial Locations (1)

34298

Institut regional du Cancer - Val d Aurelle, Montpellier

All Listed Sponsors
lead

Institut du Cancer de Montpellier - Val d'Aurelle

OTHER

NCT02135159 - Patients With Brain Metastases From HER2-positive Breast Cancer | Biotech Hunter | Biotech Hunter